Staphylococcus aureus-Cure-Associated Antigens Elicit Type 3 Immune Memory T Cells

Area of Science:

• Veterinary Immunology
• Bacterial Pathogenesis
• Vaccine Development

Background:

• *Staphylococcus aureus* is a primary cause of bovine mastitis globally.
• Current treatments and vaccines for *S. aureus* mastitis have limited efficacy.
• Investigating novel vaccine strategies targeting key *S. aureus* proteins is critical.

Purpose of the Study:

• To evaluate the immunological response to recombinant *S. aureus* proteins (PGK, ENO, EF-G) combined with GM-CSF DNA vaccination.
• To assess the potential of these antigens in eliciting a protective immune response against *S. aureus*.

Main Methods:

• C57BL/6 mice were divided into four vaccination groups (control, GM-CSF DNA, protein combination, protein + DNA vaccine).
• Spleen cells were analyzed for immunophenotyping and lymphocyte proliferation via flow cytometry after *S. aureus* stimulation.
• Key immune markers, including IL-17A production, were quantified.

Main Results:

• Immunization with the three *S. aureus* recombinant proteins induced a significant increase in IL-17A+ cells within CD8+ T central memory cells.
• The combined protein vaccination demonstrated the highest intensity of IL-17A production by overall lymphocytes.
• These findings indicate the crucial role of lymphocyte populations in establishing type 3 cell immunity.

Conclusions:

• The immunization strategy using three *S. aureus*-cure-associated recombinant proteins successfully triggered type 3 immunity.
• This approach represents a highly promising avenue for developing an effective vaccine against bovine *S. aureus* mastitis.
• Further research into this type 3 immunity pathway could lead to improved mastitis control.